Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): A study protocol

BMJ Open

Volumn 4, Issue 9, 2014, Pages

  Gunnell, Anthony S ^a   Knuiman, Matthew W ^a   Geelhoed, Elizabeth ^a   Hobbs, Michael S T ^a   Katzenellenbogen, Judith M ^a   Hung, Joseph ^b   Rankin, Jamie M ^c   Nedkoff, Lee ^a   Briffa, Thomas G ^a   Ortiz, Michael ^d   Gillies, Malcolm ^e   Cordingley, Anne ^a   Messer, Mitch ^f   Gardner, Christian ^a   Lopez, Derrick ^a   Atkins, Emily ^a   Mai, Qun ^g   Sanfilippo, Frank M ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e MedicineInsight NPS MedicineWise   (Australia)

^f Aboriginal Health Council of WA   (Australia)

^g DEPARTMENT OF HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; ATORVASTATIN; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARDIOVASCULAR AGENT; CARVEDILOL; CLOPIDOGREL; ENALAPRIL; EPROSARTAN; FLUINDOSTATIN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; METOPROLOL; OLMESARTAN; PERINDOPRIL; PRASUGREL; PRAVASTATIN; PROPRANOLOL; QUINAPRIL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; TELMISARTAN; TICAGRELOR; TRANDOLAPRIL; WARFARIN; CARDIOTONIC AGENT;

AGED; ARTICLE; AUSTRALIA; AUSTRALIAN; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG INFORMATION; EMERGENCY CARE; GOVERNMENT; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; ATRIAL FIBRILLATION; CLINICAL PROTOCOL; CORONARY DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; HEART DISEASES; PROCEDURES; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; CLINICAL PROTOCOLS; COHORT STUDIES; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HEART DISEASES; HEART FAILURE; HUMANS; LONG-TERM CARE; MEDICATION ADHERENCE; SECONDARY PREVENTION; TREATMENT OUTCOME; WESTERN AUSTRALIA;

EID: 84907199596     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006258     Document Type: Article

References (50)

1. Alexander KP, Peterson ED, Granger CB, et al. Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. J Am Coll Cardiol 1998;32:2023-30.
2. Newby LK, Allen LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113:203-12.
3. Krum H, Jelinek MV, Stewart S, et al. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust 2011;194:405-9.
4. Camm AJ, Kirchhof P, Lip GY, et al.; European Heart Rhythm A, European Association for Cardio-Thoracic S. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
5. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Reducing risk in heart disease 2007 (updated 2008). Canberra: National Heart Foundation of Australia, 2008. http://www.heartfoundation.org.au/SiteCollectionDocuments/Reduce-risk-in-heart-disease-guideline.pdf
6. Amerena JV, Walters TE, Mirzaee S, et al. Update on the management of atrial fibrillation. Med J Aust 2013;199:592-7.
7. Redfern J, Hyun K, Chew DP, et al. Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New Zealand. Heart 2014;100:1281-8.
8. Gausia K, Katzenellenbogen JM, Sanfilippo FM, et al. Evidence-based prescribing of drugs for secondary prevention of acute coronary syndrome in Aboriginal and non-Aboriginal patients admitted to Western Australian hospitals. Intern Med J 2014;44:353-61.
9. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk perception and evidence-practice gaps in Australian general practice (the AusHEART study). Med J Aust 2010;192:254-9.
10. Looi KL, Chow KL, Looi JL, et al. Under-use of secondary prevention medication in acute coronary syndrome patients treated with in-hospital coronary artery bypass graft surgery. N Z Med J 2011;124:6-10.
11. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15.
12. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-86.
13. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229-33.
14. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-35.
15. Pittman DG, Tao Z, Chen W, et al. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care 2010;16:568-76.
16. Hovstadius B, Petersson G. Non-adherence to drug therapy and drug acquisition costs in a national population - a patient-based register study. BMC Health Serv Res 2011;11:326.
17. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009;169:260-8.
18. Sun SX, Ye X, Lee KY, et al. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction. Clin Ther 2008;30(Pt 2):2217-27.
19. Bitton A, Choudhry NK, Matlin OS, et al. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med 2013;126:357.e7-27.
20. Bangalore S, Steg G, Deedwania P, et al. B-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340-9.
21. Cassese S, Byrne RA, Tada T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 2012;33:3078-87.
22. Järvinen TLN, Sievänen H, Kannus P, et al. The true cost of pharmacological disease prevention. BMJ 2011;342:d2175.
23. Holman CD, Bass AJ, Rouse IL, et al. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999;23:453-9.
24. AIHW. Australian Institute of Health and Welfare. Health expenditure Australia 2011-12. Health and welfare expenditure series no 50 Cat no HWE59. Canberra: AIHW, 2013.
25. PBS Information Management Section (Department of Health). Expenditure and prescriptions twelve months to 30 June 2013. 2013.
26. Sweeny K. The impact of further PBS reforms: report to medicines Australia. Centre for Strategic Economic Studies. Victoria University. Melbourne, Australia, 2013.
27. ABS. Household expenditure on health: a snapshot, 2004-05. Canberra: Australian Bureau of Statistics (ABS) cat no. 4836.0.55.001, 2008.
28. Briffa T, Hickling S, Knuiman M, et al. Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005. BMJ 2009;338:b36.
29. Kelaher M, Taylor-Thomson D, Harrison N, et al. Evaluation of PBS medicine supply arrangements for remote area Aboriginal Health Services under S100 of the National Health Act. Canberra: Department of Health and Ageing, 2004.
30. Gunnell AS, Einarsdottir K, Sanfilippo F, et al. Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study. Heart 2013;99:1353-8.
31. Price SD, Holman CD, Sanfilippo FM, et al. Use of case-time-control design in pharmacovigilance applications: exploration with high-risk medications and unplanned hospital admissions in the Western Australian elderly. Pharmacoepidemiol Drug Saf 2013;22:1159-70.
32. Mai Q, Holman CDA, Sanfilippo F, et al. Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Med 2011;9:118.
33. WHO. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2014. Oslo, Norway: World Health Organisation, 2013.
34. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7.
35. Krousel-Wood M, Islam T, Webber LS, et al. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 2009;15:59-66.
36. Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008;46:1125-33.
37. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 2006;28:1411-24; discussion 10.
38. Ortiz MS, Calcino G, Germanos P. Compliance with warfarin therapy by Australian patients with atrial fibrillation. Value Health 2012;15:A376.
39. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
40. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9; discussion 81-90.
41. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
42. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008;167:492-9.
43. Mai Q. The use, quality and outcomes of primary health care services in Western Australian mental health clients: a population-based longitudinal study [PhD]. The University of Western Australia, 2011.
44. Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res 2005;15:1277-88.
45. Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol 2011;8:13-28.
46. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9.
47. Kumbhani DJ, Steg PG, Cannon CP, et al. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med 2013;126:693-700.e1.
48. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004-2006. Med J Aust 2008;188:224-7.
49. Roughead EE, Vitry AI, Preiss AK, et al. Assessing overall duration of cardiovascular medicines in veterans with established cardiovascular disease. Eur J Cardiovasc Prev Rehabil 2010;17:71-6.
50. Simons LA, Ortiz M, Calcino G. Long-term persistence with statin therapy: experience in Australia 2006-2010. Aust Fam Physician 2011;40:319-22.